During the recent session, Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares were 0.62 million, with the beta value of the company hitting -0.86. At the last check today, the stock’s price was $23.34, reflecting an intraday loss of -0.76% or -$0.18. The 52-week high for the SMMT share is $33.89, that puts it down -45.2 from that peak though still a striking 91.0% gain since the share price plummeted to a 52-week low of $2.10. The company’s market capitalization is $17.21B, and the average intraday trading volume over the past 10 days was 2.95 million shares, and the average trade volume was 2.22 million shares over the past three months.
Summit Therapeutics Inc (SMMT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. SMMT has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.06.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Summit Therapeutics Inc (SMMT) registered a -0.76% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.76% in intraday trading to $23.34, hitting a weekly high. The stock’s 5-day price performance is 28.25%, and it has moved by 26.86% in 30 days. Based on these gigs, the overall price performance for the year is 519.15%. The short interest in Summit Therapeutics Inc (NASDAQ:SMMT) is 19.94 million shares and it means that shorts have 9.05 day(s) to cover.
The consensus price target of analysts on Wall Street is $36, which implies an increase of 35.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $23 and $45 respectively. As a result, SMMT is trading at a discount of -92.8% off the target high and 1.46% off the low.
Summit Therapeutics Inc (SMMT) estimates and forecasts
Statistics show that Summit Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Summit Therapeutics Inc (SMMT) shares have gone up 131.34% during the last six months, with a year-to-date growth rate less than the industry average at -130.77% against 16.90.
While earnings are projected to return 70.17% in 2025.
SMMT Dividends
Summit Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Summit Therapeutics Inc insiders own 84.36% of total outstanding shares while institutional holders control 11.74%, with the float percentage being 75.09%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 240.0 institutions own stock in it. As of 2024-06-30, the company held over 23.22 million shares (or 3.309% of all shares), a total value of $181.13 million in shares.
The next largest institutional holding, with 8.82 million shares, is of VANGUARD GROUP INC’s that is approximately 1.2566% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $68.78 million.
Also, the Mutual Funds coming in first place with the largest holdings of Summit Therapeutics Inc (SMMT) shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 3.43 shares. This amounts to just over 0.47 percent of the company’s overall shares, with a $80.16 million market value. The same data shows that the other fund manager holds slightly less at 3.04, or about 0.41% of the stock, which is worth about $71.06 million.
